Vaccines currently available to the global market are Bavarian Nordic’s MVA-BN (JYNNEOS), KM Biologics’ LC16, and Emergent ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and ...

The distribution plan prioritizes the most affected regions, with the Democratic Republic of Congo receiving 85 percent of ...

Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

Up to 899,000 vaccine doses have been allocated to nine countries across Africa, including Nigeria, that have been hit hard ...

The WHO declared mpox a global public health emergency for the second time in two years in August after a new variant of the ...

As the U.K. works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. | Flush with a 50 million pound ...

One of the World Health Organization’s most important jobs is managing viral outbreaks. The rapid spread of mpox, a disease related to smallpox, is a reminder of its shortcomings. The WHO has ...

"What we need is a public health approach where we immunize populations at scale." Drugmaker Bavarian Nordic, which makes the ...

COPENHAGEN, Denmark, October 29, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN ® mpox/smallpox vaccine in children 2 to 11 years of age.